Standout Papers

FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC 2021 2026 2022 2024179
  1. FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC (2021)
    Erica C. Nakajima, Nicole Drezner et al. Clinical Cancer Research

Immediate Impact

58 standout
Sub-graph 1 of 23

Citing Papers

Macrophage plasticity: signaling pathways, tissue repair, and regeneration
2024 Standout
Targeting KRAS in cancer
2024 Standout
2 intermediate papers

Works of Xiaoxue Li being referenced

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC
2021 Standout
SETD2 epidermal deficiency promotes cutaneous wound healing via activation of AKT/mTOR Signalling
2021

Author Peers

Author Last Decade Papers Cites
Xiaoxue Li 562 342 207 283 112 1.7k
Kun Yu 622 190 244 397 83 2.0k
Giuseppe Santoro 477 265 199 306 112 2.1k
Damien Masson 418 286 445 391 80 1.7k
J.H.H. Thijssen 379 301 171 245 85 2.1k
Ning Qu 656 256 182 256 105 2.0k
Maria Lambropoulou 433 240 135 135 176 1.9k
George I. Gorodeski 646 149 196 144 84 2.2k
Bin Wu 779 156 148 193 104 1.6k
Stefania Marsico 618 548 140 158 53 2.0k
Walter Kühn 320 266 130 248 89 1.5k

All Works

Loading papers...

Rankless by CCL
2026